JAMA Dermatology

<jats:p>This economic evaluation examines the use, price, spending, and potential spending for roflumilast and apremilast from 2014 through 2024.</jats:p>

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis-a randomized controlled trial (PSORRO).

Lancet Reg Health Eur

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

J Am Acad Dermatol

Potential Medicare and Medicaid savings on anti-CD20 therapy for multiple sclerosis.

JAMA Neurol

International regulatory and publicly-funded initiatives to advance drug repurposing.

Front Med (Lausanne)

Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016.

JAMA Intern Med

This economic evaluation examines the use, price, spending, and potential spending for roflumilast and apremilast from 2014 through 2024.

Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease.

Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease

Prices and Spending for Phosphodiesterase 4 Inhibitors in Pulmonary and Dermatologic Disease

Clinical Summary

What was studied

Related Questions